Chartwell Investment Partners LLC Buys New Holdings in Aquestive Therapeutics, Inc. (NASDAQ:AQST)

Chartwell Investment Partners LLC purchased a new stake in shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm purchased 107,550 shares of the company's stock, valued at approximately $535,000. Chartwell Investment Partners LLC owned about 0.12% of Aquestive Therapeutics as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently modified their holdings of AQST. Vanguard Group Inc. raised its position in Aquestive Therapeutics by 71.7% during the 1st quarter. Vanguard Group Inc. now owns 3,242,571 shares of the company's stock worth $13,813,000 after purchasing an additional 1,353,518 shares during the last quarter. Blue Owl Capital Holdings LP raised its position in shares of Aquestive Therapeutics by 30.3% during the second quarter. Blue Owl Capital Holdings LP now owns 1,140,000 shares of the company's stock worth $2,964,000 after acquiring an additional 265,000 shares during the last quarter. Bank of New York Mellon Corp acquired a new position in shares of Aquestive Therapeutics in the second quarter worth approximately $594,000. Deerfield Management Company L.P. Series C acquired a new position in shares of Aquestive Therapeutics in the 2nd quarter worth approximately $380,000. Finally, Rhumbline Advisers bought a new stake in Aquestive Therapeutics during the second quarter valued at $254,000. Institutional investors and hedge funds own 32.45% of the company's stock.

Aquestive Therapeutics Stock Performance

Aquestive Therapeutics stock traded down $0.26 during midday trading on Thursday, reaching $4.57. 1,951,040 shares of the stock were exchanged, compared to its average volume of 1,754,812. The company's fifty day moving average is $4.98 and its 200-day moving average is $3.86. Aquestive Therapeutics, Inc. has a 52 week low of $1.55 and a 52 week high of $6.23. The firm has a market cap of $416.68 million, a PE ratio of -10.16 and a beta of 2.82.

Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) last posted its quarterly earnings data on Monday, November 4th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.01). The company had revenue of $13.54 million during the quarter, compared to the consensus estimate of $12.69 million. During the same period last year, the company earned ($0.03) earnings per share. On average, sell-side analysts anticipate that Aquestive Therapeutics, Inc. will post -0.47 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the company. HC Wainwright restated a "buy" rating and set a $10.00 price target on shares of Aquestive Therapeutics in a report on Wednesday, November 6th. JMP Securities reissued a "market outperform" rating and set a $9.00 price target on shares of Aquestive Therapeutics in a research report on Tuesday, October 8th. Finally, Leerink Partners lifted their price objective on shares of Aquestive Therapeutics from $12.00 to $13.00 and gave the stock an "outperform" rating in a research report on Friday, October 25th. Five analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average target price of $9.80.

Aquestive Therapeutics Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.